Acepodia: AcePodia, Inc. Provides Update on Collaboration Under the Pfizer Ignite Program

On September 3, 2024, Acepodia entered into a strategic clinical collaboration with Pfizer Ignite to support the development of its therapies in autoimmune diseases. Pfizer Ignite is an end-to-end offering that leverages Pfizer's significant resources,scale, and expertise, to support biotechs seeking to accelerate their innovations from preclinical R&D through the development lifecycle. Following discussions, Pfizer and Acepodia have mutually agreed to terminate the collaboration. During this wind-down process, Pfizer will ensure a smooth transition,with no impact on Acepodia?s clinical development program. This decision reflects Pfizer?s global resource prioritization and is unrelated to the performance or capabilities of Acepodia?s platform. The collaboration remained in an early exploratory stage, involving preliminary clinical trial design and strategic discussions. Acepodia leads the development planning, with clinical execution to be carried out by contracted research organizations(CROs). Pfizer?s role in this collaboration to date has been primarily advisory,offering technical and strategic input. Acepodia?s clinical development programs will proceed as originally scheduled,with no material impact on the company?s financials or operations. The relationship between both parties remains positive, and future collaboration may be reconsidered should strategic alignment occur. Pfizer will ensure a smooth transition, with no impact on Acepodia?s clinical development program and the company's business development.